secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001493152-24-045373
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx Q3 2024 net loss $2.5M; cash $9.6M, trial interim analysis targeted late 2024/early 2025
--------------------------------------------------------------------------------

- Net loss of $2.5M in Q3 2024 vs $1.4M loss in Q3 2023; R&D flat at $1.7M, G&A down to $1.2M.
- Cash $9.6M at Sept 30, sufficient to fund next TIGeR-PaC interim analysis and current RenovoCath commercialization.
- Phase III TIGeR-PaC trial in LAPC: next interim analysis triggered by 52nd event (estimated late 2024/early 2025); full enrollment expected H1 2025.
- RenovoCath commercialization progressing; increased production with Medical Murray; potential near-term revenue in 2025 via direct or partner channels.
- Promoted Robert Strasser to VP R&D & Operations; enrolled first patient at University of Nebraska Medical Center for TIGeR-PaC trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315224045373/0001493152-24-045373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315224045373/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-045373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer